Clinical and Virological Features of Patients Hospitalized with Different Types of COVID-19 Vaccination in Mexico City.
COVID-19
COVID-19 severity
SARS-CoV-2 lineages
comorbidities in COVID-19
vaccination schemes
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
26 Jul 2022
26 Jul 2022
Historique:
received:
09
06
2022
revised:
27
06
2022
accepted:
04
07
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
Coronavirus disease 2019 (COVID-19) vaccines effectively protect against severe disease and death. However, the impact of the vaccine used, viral variants, and host factors on disease severity remain poorly understood. This work aimed to compare COVID-19 clinical presentations and outcomes in vaccinated and unvaccinated patients in Mexico City. From March to September 2021, clinical, demographic characteristics, and viral variants were obtained from 1014 individuals with a documented SARS-CoV-2 infection. We compared unvaccinated, partially vaccinated, and fully vaccinated patients, stratifying by age groups. We also fitted multivariate statistical models to evaluate the impact of vaccination status, SARS-CoV-2 lineages, vaccine types, and clinical parameters. Most hospitalized patients were unvaccinated. In patients over 61 years old, mortality was significantly higher in unvaccinated compared to fully vaccinated individuals. In patients aged 31 to 60 years, vaccinated patients were more likely to be outpatients (46%) than unvaccinated individuals (6.1%). We found immune disease and age above 61 years old to be risk factors, while full vaccination was found to be the most protective factor against in-hospital death. This study suggests that vaccination is essential to reduce mortality in a comorbid population such as that of Mexico.
Identifiants
pubmed: 35893830
pii: vaccines10081181
doi: 10.3390/vaccines10081181
pmc: PMC9330015
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Consejo Nacional de Ciencia y Tecnología
ID : Caracterizacion de la diversidad viral y bacteriana
Organisme : SECTEI
ID : 057
Organisme : AHF Global Public Health Institute, University of Miami
ID : Genomic surveillance for SARS-CoV-2 variants in Mexico
Références
Mol Biol Evol. 2018 Jun 1;35(6):1547-1549
pubmed: 29722887
Nature. 2021 Aug;596(7872):417-422
pubmed: 34192737
Intern Emerg Med. 2021 Sep;16(6):1507-1517
pubmed: 33411264
Microb Pathog. 2021 May;154:104831
pubmed: 33727169
Neurol Int. 2022 Apr 27;14(2):406-416
pubmed: 35645352
Sci Immunol. 2021 Aug 19;6(62):
pubmed: 34413140
J Intern Med. 2021 Jun;289(6):861-872
pubmed: 33411411
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Cell Host Microbe. 2021 Mar 10;29(3):322-324
pubmed: 33705702
Clin Infect Dis. 2021 Aug 23;:
pubmed: 34423834
Front Med (Lausanne). 2022 Jan 03;8:792135
pubmed: 35047533
Lancet Rheumatol. 2021 Oct;3(10):e724-e736
pubmed: 34485930
Front Neurol. 2021 Mar 24;12:607790
pubmed: 33841296
Eur Rev Med Pharmacol Sci. 2022 Mar;26(5):1770-1776
pubmed: 35302230
Clin Infect Dis. 2022 Apr 12;:
pubmed: 35412591
BMJ. 2022 Mar 9;376:e069761
pubmed: 35264324
Am J Emerg Med. 2020 Sep;38(9):1722-1726
pubmed: 32738466
Nucleic Acids Res. 2002 Jul 15;30(14):3059-66
pubmed: 12136088
Nat Rev Microbiol. 2021 Jul;19(7):409-424
pubmed: 34075212
Clin Chim Acta. 2020 Jul;506:145-148
pubmed: 32178975
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Euro Surveill. 2022 Mar;27(9):
pubmed: 35241215
Cerebrovasc Dis. 2021;50(2):132-140
pubmed: 33530081
Infect Chemother. 2021 Mar;53(1):155-158
pubmed: 34409789
Viruses. 2022 Mar 06;14(3):
pubmed: 35336952
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Biochem Biophys Res Commun. 2021 Jan 29;538:88-91
pubmed: 33199021
Clin Immunol. 2021 Mar;224:108651
pubmed: 33333255
J Med Virol. 2020 Sep;92(9):1562-1566
pubmed: 32222995
Sci Rep. 2020 Aug 20;10(1):14031
pubmed: 32820179
Vaccines (Basel). 2021 Sep 29;9(10):
pubmed: 34696220
J Infect Public Health. 2019 Jul - Aug;12(4):486-491
pubmed: 30670352
Int J Infect Dis. 2021 Sep;110:353-358
pubmed: 34375762
Front Immunol. 2021 Dec 06;12:758294
pubmed: 34938287
Open Forum Infect Dis. 2015 Jul 03;2(3):ofv098
pubmed: 26258155
BMJ. 2022 Mar 2;376:e068632
pubmed: 35236664
Viruses. 2021 Oct 26;13(11):
pubmed: 34834967
J Clin Med. 2022 Feb 23;11(5):
pubmed: 35268282
Proc Natl Acad Sci U S A. 2022 Mar 1;119(9):
pubmed: 35193979
Microbiol Spectr. 2022 Feb 23;10(1):e0124921
pubmed: 35019701
Arch Virol. 2021 Nov;166(11):3173-3177
pubmed: 34448936
Adv Chronic Kidney Dis. 2020 Sep;27(5):365-376
pubmed: 33308501
Front Med (Lausanne). 2022 Feb 22;9:815389
pubmed: 35273977
Viruses. 2021 Oct 29;13(11):
pubmed: 34834987
Front Immunol. 2021 Nov 05;12:744242
pubmed: 34804024
Microorganisms. 2021 Oct 18;9(10):
pubmed: 34683488
Front Immunol. 2021 Nov 03;12:742167
pubmed: 34804022
mBio. 2021 Jan 19;12(1):
pubmed: 33468702